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Abstract
Approximately half of all melanoma patients harbour activating mutations in the serine/threonine kinase BRAF. This is
the basis for one of the main treatment strategies for this tumor type, the targeted therapy with BRAF and MEK
inhibitors. While the initial responsiveness to these drugs is high, resistance develops after several months, frequently
at sites of the previously responding tumor. This indicates that tumor response is incomplete and that a certain tumor
fraction survives even in drug-sensitive patients, e.g., in a therapy-induced senescence-like state. Here, we show in
several melanoma cell lines that BRAF inhibition induces a secretome with stimulating effect on ﬁbroblasts and naive
melanoma cells. Several senescence-associated factors were found to be transcribed and secreted in response to BRAF
or MEK inhibition, among them members of the ﬁbroblast growth factor family. We identiﬁed the growth factor FGF1
as mediator of resilience towards BRAF inhibition, which limits the pro-apoptotic effects of the drug and activates
ﬁbroblasts to secrete HGF. FGF1 regulation was mediated by the PI3K pathway and by FRA1, a direct target gene of the
MAPK pathway. When FGFR inhibitors were applied in parallel to BRAF inhibitors, resilience was broken, thus providing
a rationale for combined therapeutical application.
Introduction
The treatment of metastatic melanoma is currently
based on two main pillars: targeted therapy addressing
BRAF (v-Raf murine sarcoma viral oncogene homolog B)/
MEK (Mitogen-activated protein kinase kinase) in BRAF-
mutant melanoma patients, and immune therapy, applied
irrespective of the driver mutation. For patients with
BRAF-mutant tumors and a high tumor load, targeted
therapy is frequently preferred, as therapy responsiveness
occurs more quickly. Unfortunately, acquired as well as
intrinsic resistance mechanisms limit the beneﬁt of BRAF/
MEK inhibitor therapy.
Mutational activation of the RAS (RAS viral oncogene
homolog)/RAF (Rapidly Accelerated Fibrosarcoma
kinase/MAPK (Mitogen activated protein kinase) path-
ways occurs in the majority of melanomas with acquired
resistance. These mutations are the result of extended
drug-induced selection processes. Most frequently, acti-
vating NRAS (Neuroblastoma RAS viral oncogene
homolog), MEK1 and MEK2 mutations or BRAF ampli-
ﬁcations are detected1–4. In contrast, intrinsic resistance is
mostly caused by transcriptional rewiring of signaling
pathways. Negative feedback regulators such as SPRO-
UTY and SPRED family proteins are re-activated in
response to MAPK inhibition, thereby increasing RAS
activity and the responsiveness to growth factors5,6. Fur-
thermore, the increased expression of receptor tyrosine
kinases (RTK) like PDGFRB (Platelet derived growth
factor receptor beta), EGFR (Epidermal growth factor
receptor), MET (c-Met or hepatocyte growth factor
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receptor), and AXL (AXL receptor tyrosine kinase), which
are induced due to the high phenotypic plasticity of
melanomas and driven by diverse transcription factors,
are correlated with reduced drug responsiveness7–10. In
particular, high AXL expression, frequently in combina-
tion with low MITF (Microphthalmia transcription factor)
levels, seems to predispose melanomas to resistance
against BRAF/MEK inhibitors11–13.
But even in BRAFV600E/K melanoma cells responding to
BRAF inhibition, the anti-tumorigenic effect is limited, as
apoptosis induction is incomplete. As a result, a fraction
of melanoma cells survives, leading to disease relapse at
the original metastatic sites14. Survival of cells under
targeted therapy is likely favored by adaptive signaling
crosstalk, which occurs under MAPK pathway inhibition
and was shown to be beneﬁcial for melanoma cell survival
under stress conditions5,15. We and others have further-
more demonstrated that BRAF inhibition causes pre-
mature senescence in vitro and in vivo16,17. While
senescence is generally considered anti-tumorigenic due
to growth inhibition of the affected cell population,
senescent cells have the potential to affect the surround-
ing tumor niche in a favorable manner. An enhanced
secretory activity is one of the hallmarks of senescence.
This senescence-associated secretory phenotype (SASP)
leads to the secretion of cytokines and growth factors,
which can—depending on the cellular context—positively
or negatively affect tumor growth18–20.
In this study, we investigated the effect of BRAF/MEK
inhibition in drug-responsive melanoma cells on the
induction of SASP-like secreted factors. Our aim was the
identiﬁcation of targets, whose inhibition has the potential
to improve anti-BRAF/MEK therapy.
Results
BRAF-inhibitor-conditioned medium favors cell growth
The secretion of factors under conditions of therapy
stress harbours the potential to inﬂuence neighbouring
cells in either positive or negative manners. In vivo,
therapy-responsive melanoma cells are frequently
accompanied by ﬁbroblasts or by heterogenous popula-
tions of non-responsive melanoma cells, which coexist in
Fig. 1 Treatment of melanoma cells with conditioned supernatant. a Conditioned supernatant (cond. SN) was generated from melanoma cells
treated for 3 days with vemurafenib (vem, 0.5 µM) and from DMSO-treated control cells (ctrl). Donor cells were seeded to achieve an equal
conﬂuency at day 3. After excessive washing with PBS, donor cells were starved over night with medium containing 2% dialysed FCS. The following
day, acceptor cells (which were starved for 3 days) were treated with ﬁltered conditioned supernatant for 48 h followed by MTT measurement. b
Western blot showing P-ERK1/2 (Thr202/Tyr204) of UACC-62 cells treated for 3 days with indicated concentrations of vemurafenib. Actin served as
loading control. c MTT assays of the melanoma cell lines M14, UACC62, A375 and the ﬁbroblast cell line WI-38 treated for 48 h with DMSO (“ctrl SN”)
and vemurafenib-conditioned supernatant (“vem SN”). mel: melanoma; fb: ﬁbroblast. Data are derived from three independent experiments. *p <
0.05; **p < 0.01; ***p < 0.001 (Student’s t-test, unpaired, comparison between vemurafenib-conditioned and control conditioned supernatant, which
was set as 100%)
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the same tumor niche. To test the inﬂuence of BRAF
inhibitor-induced factors on other cells, we developed a
test system involving donor cells, which are treated with
the BRAF inhibitor vemurafenib to generate vemurafenib-
conditioned supernatant, and acceptor cells, which are
treated with this conditioned supernatant (Fig. 1a). To
avoid a negative effect of apoptotic donor cells on
acceptor cells, donor cells were treated with 0.5 µM
vemurafenib. At this concentration, apoptosis is reduced,
while a strong senescence response16 and ERK1/2 inhi-
bition (Fig. 1b) are observed. The three BRAFV600E mutant
cell lines UACC-62, M14, and A375 were used as donor
cell lines. When conditioned medium from melanoma
cells was added to vemurafenib-naive melanoma cells or
the ﬁbroblast-like cell line WI-38 as acceptor cell lines,
vemurafenib-conditioned supernatant led to an enhanced
viability of acceptor cells compared to control supernatant
in almost all cases (Fig. 1c). As the absolute cell number
also increased, as exemplarily shown for A375 condi-
tioned supernatant (Supplementary Figure 1), we con-
cluded that vemurafenib-conditioned supernatant has a
growth-promoting effect on target cells.
Transcription of pro-tumorigenic factors by BRAF
inhibition
To test the inﬂuence of BRAF inhibition on SASP genes,
we ﬁrst generated a list of overlapping SASP genes, which
are induced by various different senescence trig-
gers18,19,21,22, and which includes cytokines, growth fac-
tors and proteases/protease receptors (Fig. 2a). The
melanoma cell lines M14, UACC-62, and A375 were
treated with vemurafenib for three days, and gene
expression was monitored by real-time PCR. We focused
on those genes, which were signiﬁcantly regulated by
vemurafenib by at least factor two, and which were
regulated in at least two of the three cell lines. Four genes
met these criteria. CXCL8 (encoding interleukin 8) was
strongly suppressed in all three cell lines. In contrast, CC-
chemokine ligand 2 (CCL2) and matrix metalloprotease 2
(MMP2) were upregulated by BRAF inhibition in all cases,
and ﬁbroblast growth factor 1 (FGF1) was upregulated in
two cell lines (Fig. 2a). Of note, CCL2, MMP2, and FGF1
have all been assigned pro-tumorigenic features.
In melanoma patients, dual BRAF/MEK inhibition has
become standard of care treatment for BRAFV600E/K
positive patients due to the prolonged tumor response
compared to BRAF inhibitor monotherapy23. We there-
fore tested senescence response and gene induction of
CCL2, MMP2, and FGF1 under conditions of single and
combined BRAF and MEK inhibition in A375 cells. A
solid downregulation of P-ERK/2 was observed in all cases
(Fig. 2b). Importantly, senescence-associated β-galactosi-
dase (β-Gal) staining and the induction of CCL2, MMP2,
and FGF1 were detected under all conditions (Fig. 2c, d).
Similar observations were obtained for M14 cells (with
the exception of FGF1, which is not induced in this cell
line), and for UACC-62 cells, which showed a trend
towards CCL2 and MMP2 upregulation as well as sig-
niﬁcant FGF1 induction under conditions of BRAF and/or
MEK inhibition (Supplementary Figure 2A–E). MMP2
was previously described to be induced in melanoma after
MEK inhibition24, and we could conﬁrm the secretion of
the protease in the supernatant of vemurafenib-treated
cells (Supplementary Figure 3A). Furthermore, the
observed induction of CCL2 and the reduction of IL8
RNA expression were conﬁrmed on protein level by
ELISA in the supernatant of A375 cells (Supplementary
Figure 3B).
Deregulation of multiple ﬁbroblast growth factors by BRAF
inhibition
As FGFs are potent growth factors with multiple effects
on different cell types of the melanoma microenviron-
ment, we were interested to investigate if other FGFs are
induced by BRAF inhibition in melanoma cells in addition
to FGF1. To this end, we tested multiple cancer-relevant
FGFs in the three melanoma cell lines using a growth
factor PCR array. We could conﬁrm the induction of
FGF1 in UACC-62 and A375 cells. Interestingly, a >2-fold
upregulation was also detected for FGF7 in these two cell
lines (Fig. 3a), but not in M14 cells. In addition, we
observed a weak induction of FGF17 in all three cancer
cell lines, though only at low levels, which could be
detected by RT-PCR after extended rounds of ampliﬁca-
tion (Supplementary Figure 4A), but not by ELISA of
either supernatant or cell lysate. Therefore, we excluded a
relevant role of FGF17 for cellular resilience. In contrast,
BRAF inhibitor-induced FGF1 and FGF7 secretion was
clearly detected by ELISA, as exempliﬁed in A375 cells
(Fig. 3b). FGFs show different binding characteristics
towards their high-afﬁnity ﬁbroblast growth factor
receptors (FGFR) 1-4. FGF1 is able to bind all four
receptors, while FGF7 only binds to FGFR225,26. Semi-
quantitative analysis of cDNA from melanoma cells and
the ﬁbroblast cell line MainUro revealed that FGFR1 is
expressed in all analysed cell lines, while FGFR2-4 are
expressed variably (Supplementary Figure 4B). In a sub-
sequent real-time PCR, we analysed the delta cT value
between the respective FGFR and the housekeeping gene
and conﬁrmed these observations (Supplementary Figure
4C). This implies that FGF1 is most likely the relevant
factor, which impacts melanoma cells as well as ﬁbro-
blasts. BRAF-inhibitor-induced expression of FGF1 was
furthermore seen in an independent publicly available
dataset using melanoma cell lines, which were treated
with 0.25 µM vemurafenib for 8 h (Fig. 3c)27. However,
the data did not reach statistical signiﬁcance due to the
high variations in expression levels between cell lines. To
Grimm et al. Oncogenesis  (2018) 7:71 Page 3 of 12
Oncogenesis
get better insight into a potential link between the RAF/
MAPK pathway inhibition and FGF1 expression in a lar-
ger set of melanoma cell lines, we treated M14, UACC-62,
and A375 cell lines as well as four additional melanoma
cell lines for 24 h with vemurafenib (0.5 µM) or the MEK
inhibitors PD184352 (2 µM) and trametinib (50 nM),
respectively (Fig. 3d). We chose this shorter treatment
instead of our standard 3-day treatment, as the dataset
Fig. 2 Expression of different secretome associated genes after BRAF-inhibitor or MEK inhibitor treatment. a Expression of different
secretome associated genes after vemurafenib treatment. M14, UACC-62 and A375 were treated with vemurafenib or DMSO for 72 h. mRNA levels of
the secretome associated genes were determined by real-time PCR. Gray color marks genes, which are regulated more than two-fold in at least two
of the three cell lines and whose regulation reached signiﬁcance. **p < 0.01 (Student’s test, unpaired, comparison with respective untretaed control).
bWestern blot showing P-ERK1/2 (Thr202/Tyr204) of A375 cells treated with vemurafenib (0.5 µM), PD184352 (0.5 µM) or both for one and three days.
Tubulin served as loading control. c A375 cells were treated for 72 h with the MEK inhibitor PD184352 (0.5 µM) and/or vemurafenib (0.5 µM), after
which SA-β-Gal staining was performed. Left: representative images; right: corresponding quantiﬁcation (One-way ANOVA: p < 0.0001; post hoc test:
t-test, unpaired, data derived from three independent experiments). d Corresponding expression of the secretome associated genes, as determined
by real-time PCR (One-way ANOVA: p < 0.05, post hoc test: t test, unpaired, data derived from at least four independent experiments) *p < 0.05; **p <
0.01; ***p < 0.001. vem: vemurafenib. PD: PD184352
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from Joseph and colleagues indicated that the effect of
BRAF inhibition on FGF1 already occurs at early time-
points27. With the exception of M14 cells, FGF1 was
induced in all BRAF- but not NRAS-mutant cell lines in
response to BRAF inhibition. Furthermore, MEK inhibi-
tion by either PD184352 or trametinib induced FGF1 in
six of seven cell lines, again with the exception of M14
cells. This was also observed for SK-MEL-2, the only
NRAS-mutated cell line in this cohort, thus demonstrat-
ing that FGF1 induction is a common response to MAPK
pathway inhibition (Fig. 3d).
To test whether FGF1 affects the sensitivity of mela-
noma cells to BRAF inhibition, we treated the melanoma
cell lines M14, UACC-62, and A375 for 5 days with 2 µM
vemurafenib in absence or presence of AZD4547, FGF1 or
a combination of both (Fig. 4a). In all cases, the cell
number was signiﬁcantly increased in presence of FGF1.
The protective effect of FGF1 was reversed in presence of
the FGFR inhibitor AZD4547. AZD4547 treatment alone
reduced the cell number in UACC-62 and A375 cell lines.
This effect was also seen in presence of 0.5 µM
vemurafenib (Supplementary Figure 5A), but less pro-
nounced. Even M14 cells, which show no induction of
FGF1 in response to vemurafenib, were protected by
exogenous FGF1 (Fig. 4a and Supplementary Figure 5A).
However, AZD4547 alone only showed a weak effect on
sensitivity towards vemurafenib, which did not reach
signiﬁcance under any vemurafenib concentration in M14
cells (compare “ctrl” and “AZD” in Fig. 4a and Supple-
mentary Figure 5A). In absence of BRAF inhibition, cell
viability was not affected by FGF1 (Supplementary Figure
5B). Moreover, the growth-promoting effect of
vemurafenib-conditioned medium on melanoma cells was
prevented when AZD4547 was applied simultaneously
(Fig. 4b).
FGF1 has been described as potent mitogenic growth
factor for ﬁbroblasts. Accordingly, FGF1 signiﬁcantly
enhanced cell viability in MainUro and NHDF ﬁbroblasts
(Fig. 4c). Activated ﬁbroblasts can be triggered to secrete
microenvironment-remodeling factors, including HGF
(hepatocyte growth factor), which plays a crucial role in
mediating BRAF inhibitor resistance28–30. We therefore
Fig. 3 BRAF inhibition alters the FGF pathway. a Alterations of mRNA levels of indicated FGFR ligands, as measured by human growth factor PCR
array, after treatment of M14, UACC-62, and A375 for 3 days with vemurafenib (0.5 μM). b Secretion of FGF1 and FGF7 in A375 cells treated with
vemurafenib for 3 days (0.5 µM). Samples were measured by ELISA and are derived from two (FGF1) to three (FGF7) independent experiments.
c Analysis of FGF1 expression in the publicly available data set GSE20051 (n= 5) of melanoma cells exposed to 0.25 µM PLX4032 (vemurafenib) for
8 h. In the boxplot ﬁgure, the median value (in the box), the ﬁrst and third quartile (upper and lower border of the box), and the minimum values are
indicated. Maximum values are represented as outliers. d Real-time PCR of FGF1 in indicated melanoma cell lines after 24 h of treatment with
vemurafenib (0.5 µM) or the MEK inhibitors PD184352 (2 µM) or trametinib (50 nM). Data are derived from 2–5 independent experiments, each
performed in triplicate, and are referred to control cells treated with the solvent DMSO. *p > 0.05; **p > 0.01
Grimm et al. Oncogenesis  (2018) 7:71 Page 5 of 12
Oncogenesis
Fig. 4 Paracrine effects of FGF1. a Sensitivity towards vemurafenib in presence of FGF1 and FGF inhibitor AZD4547. Cells were treated with
vemurafenib (2 µM) in absence or presence of FGF1 (100 ng/ml) and AZD4547 (100 ng/ml) for 5 days. Medium was changed every 2 days. After
5 days, cells were counted. Data are derived from three independent experiments (One-way ANOVA: p < 0.05, post hoc test: t test, unpaired).
b Viability of M14 melanoma cells, treated with control- or vemurafenib (0.5 µM)-conditioned supernatant of A375 cells for 2 days. Left image: scheme
of the experimental setup. Right: corresponding quantiﬁcation. Where indicated, FGFR inhibitor AZD (100 ng/µl) was added. (One-way ANOVA: p <
0.05, post hoc test: t test, unpaired). c MTT assay of MainUro ﬁbroblasts and normal human dermal ﬁbroblasts (NHDF) after treatment with
recombinant FGF1 (100 ng/ml) for 5 days. Cells were starved in medium containing 2% FCS before FGF1 treatment. 1 × 103 cells were seeded per 96
well and medium with the recombinant ligand was changed after 48 h. Signiﬁcant differences are referred to the respective untreated control, which
was set as 100%. d Real-time PCR of HGF in MainUro ﬁbroblasts treated with FGF1, FGF7, FGF17 or a combination of these (100 ng/ml, 8 h). Data are
normalized to the untreated controls and are derived from four independent experiments. e HGF secretion of MainUro cells after FGF1 treatment
(100 ng/ml, 2 days), as measured by ELISA. Data are derived from three independent experiments. f Analysis of HGF secretion of MainUro ﬁbroblasts
in response to conditioned supernatant from melanoma cells. Left: Scheme of the experimental setup. Middle: HGF expression in MainUro cells
treated for 2 days with conditioned control medium (ctrl) or vemurafenib-conditioned medium from A375 cells (vem) (see also Fig. 1). Where
indicated, AZD4547 (100 nM) was added to MainUro cells (at the same time as vemurafenib-conditioned medium was applied). Right: Corresponding
HGF secretion, as determined by ELISA. Data are derived from three independent experiments. Statistical analysis was done using One-way ANOVA
(p < 0.0001; post hoc test: t test). *p < 0.05; **p < 0.01, ***p < 0.001
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checked whether any of the FGFs, which are increased in
response to BRAF inhibition, have an inﬂuence on HGF
expression in ﬁbroblasts. Recombinant human FGF1, but
not FGF7 and FGF17, signiﬁcantly induced HGF expres-
sion in ﬁbroblasts (Fig. 4d). The same degree of HGF
upregulation was observed when a combination of all
three FGFs was applied. Importantly, FGF1-dependent
HGF secretion was also detected on protein level (Fig. 4e).
When vemurafenib-conditioned supernatant from A375
cells was applied to ﬁbroblasts, HGF was also induced on
transcriptional as well as on protein level (Fig. 4f). This
induction was prevented in presence of the FGFR
Fig. 5 Involvement of PI3K pathway in vemurafenib-induced secretome. a Western blot of P-AKT (Ser473), P-ERK p42/44 (Thr202/Tyr204) and β-
actin (loading control) in A375 cells, treated for 3 days with 0.5, 2 or 5 µM vemurafenib. b SA-β-Gal staining of A375 cells treated for 3 days with
vemurafenib (0.5 µM) and/or the dual PI3K/mTOR inhibitor BEZ-235 (0.5 µM), as indicated. Left: representative images; right: corresponding
quantiﬁcation (One-way ANOVA: p < 0.0001; post hoc test: t test, unpaired, data derived from three independent experiments). c Corresponding real-
time PCR of FGF1, MMP2, and CCL2. d SA-β-Gal staining of A375 cells treated for 3 days with vemurafenib (0.5 µM) and/or the PI3K inhibitor GDC-0941
(4 µM), as indicated. Left: representative images; right: corresponding quantiﬁcation. e Corresponding real-time PCR of FGF1, MMP2, and CCL2 (d, e:
One-way ANOVA: p < 0.0001; post hoc test: t test, unpaired, data derived from three independent experiments). v: vemurafenib; B: BEZ-235; G: GDC-
0941
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inhibitor AZD4547. Together, FGF1 has beneﬁcial effects
on melanoma cells and ﬁbroblasts, thereby limiting the
efﬁcacy of BRAF inhibition.
Involvement of PI3K and FRA1 in the transcription of
secreted factors
BRAF or MEK inhibition in BRAF-mutant melanoma
cells leads to immediate crosstalk mechanisms, including
the RAS-mediated activation of the PI3K pathway5,31,32.
This can be detected as an increase in phosphorylated
AKT (Fig. 5a). To test if this compensatory pathway
affects the expression of the secreted factors, we used the
dual mTOR/PI3K inhibitor BEZ-235 (“BEZ”) in combi-
nation with vemurafenib. Interestingly, BEZ prevented the
senescence-associated β-Gal staining by vemurafenib
along with the induction of FGF1, MMP2, and CCL2 (Fig.
5b, c). The PI3K inhibitor GDC-0941 led to the same
effect (Fig. 5d, e), suggesting that the transcription of
protective factors by BRAF inhibition is mediated by the
PI3K pathway.
In a previous study by Obenauf and colleagues, the
inﬂuence of vemurafenib-responsive A375 cells on
vemurafenib-resistant A375R cells was investigated. In
this context, the authors identiﬁed a set of genes, which
was induced by vemurafenib treatment in A375 cells.
They also observed CCL2 induction, but no effect on
MMP2 or FGFs33. The authors reported that the AP-1
transcription factor component FRA1, which is tran-
scribed and activated downstream of ERK1/2 and is
suppressed by vemurafenib in our cell lines (Fig. 6a), is
responsible for the detected gene induction33. We tested
this hypothesis by siRNA-mediated knockdown in an
independent melanoma cell line. Using UACC-62 cells,
we analysed those genes, whose corresponding gene
products were detectably secreted in our study, namely
MMP2, CCL2, FGF1, and FGF7. Only FGF1 was sig-
niﬁcantly upregulated by siRNA-mediated knockdown of
FOSL1, the gene encoding FRA1 (Fig. 6b). Recently, we
described the effect of FRA1 expression on non-
transformed melan-a melanocytes and performed tran-
scriptome analysis of melan-a cells after 3 and 16 days of
FRA1 expression34. Expression data from this analysis
showed that FGF1 is consistently repressed in response to
FRA1, while MMP2 and CCL2 are not or inconsistently
regulated by FRA1, and FGF7 expression was too low for
analysis (Fig. 6c and Supplementary Figure 6). These data
Fig. 6 FRA1 as regulator of FGF1. a Real-time PCR of FOSL1 in indicated melanoma cell lines after three days of vemurafenib treatment. Data are
derived from two independent experiments and are referred to control cells treated with the solvent DMSO. b Real-time PCR of FOSL1, MMP2, a FGF1,
CCL2 and FGF7 in UACC-62 cells after siRNA-mediated knockdown of FOSL1 for 3 days, using smartpool siRNA. Data are derived from three different
experiments. Signiﬁcant differences are calculated between knockdown and the corresponding control siRNA experiment. c RNASeq results from
melan-a FOSL1 cells, expressing doxycycline (Dox)-inducible FOSL1 in response to Dox (1 µg/ml) for 3 and 16 days. Data are derived from34 (GEO
accession number GSE85086). d Schematic overview of the FGF1-driven BRAF inhibitor resilience
Grimm et al. Oncogenesis  (2018) 7:71 Page 8 of 12
Oncogenesis
demonstrate that FGF1 is jointly induced by PI3K path-
way and FRA1 repression, while PI3K, but not FRA1,
contributes to the expression of CCL2 and MMP2.
Discussion
Inhibition of the BRAF/MEK pathway in melanomas
constitutes an important treatment option for BRAF-
mutant melanomas. Although BRAF-mutant drug-sensi-
tive melanomas show increased apoptosis in response to
BRAF or BRAF/MEK inhibition in vitro and in vivo, a
sufﬁcient number of cells frequently remains to allow the
outgrowth of resistant melanomas at their original
site14,35. One reason for tumor cell survival might be the
fact that blocking BRAF/MEK causes premature senes-
cence, a cellular state hard to attack by standard ther-
apy16,17. Here we show that melanoma cells treated with
the BRAF inhibitor vemurafenib secrete factors, which
stimulate naive melanoma cells and ﬁbroblasts, thereby
limiting the anti-tumorigenic effect of BRAF inhibition.
We identiﬁed FGF1 as novel mediator of BRAF inhibitor
resilience (summarized in Fig. 6d).
The concept of a therapy-induced as well as a
senescence-associated secretome was previously observed
in melanoma. The chemotherapeutical agent cisplatin
leads to a SASP, thereby exerting a positive effect on non-
senescent melanoma cells36. Accordingly, premature
senescence caused by the knockdown of the melanocyte
lineage factor MITF stimulated a SASP, which had the
capacity to convey melanoma cells with tumor initiating
and metastatic features in a mouse model20,22. Interest-
ingly, MITF knockdown also led to increased CCL-2
levels, which were involved in the tumor-promoting
effect20.
Obenauf and collegues analysed the effect of
vemurafenib-sensitive cell lines on vemurafenib-resistant
cancer cells. They described that drug-sensitive A375
melanoma cells secrete various cytokines and stimulate
growth and metastasis of drug-resistant A375 cancer cell
clones33. Growth promotion of vemurafenib-resistant by
vemurafenib-sensitive melanoma cells was furthermore
conﬁrmed with various cell lines. The coexistence of
intrinsically drug-resistant as well as drug-sensitive mel-
anoma cells at one site is a known phenomenon in clinical
practice. It is due to the presence of heterogenous cell
populations within one patient's tumor, e.g., cell clones
harboring BRAF mutations and others comprising NRAS
mutations. Our data now show that the secretome of
vemurafenib-sensitive cells also has the potential to sti-
mulate ﬁbroblasts and naive melanoma cells. While this
effect is most likely mediated by several factors, we
identiﬁed FGF1 as one important contributing secretome
component. FGF1 could limit the inhibitory effect of
vemurafenib on melanoma cells, while the simultaneous
inhibition of BRAF and FGF receptors increased the anti-
tumorigenic effect. It was previously described that BRAF
inhibition is able to induce the unfolded protein response
(UPR) in melanoma cells37. Interestingly, another study
recently demonstrated that the UPR can trigger the
expression of FGF1 and FGF2 in melanoma cells38, thus
raising the possibility that the BRAF inhibition causes
UPR next to senescence and thereby leads to the secretion
of protective FGF1. Potential differences in UPR between
different cell lines could explain why some cells are potent
FGF1 inducers after BRAF/MEK inhibitor treatment (e.g.,
A375 cells), why others are not (e.g., M14 cells).
Our study shows that BRAF inhibition triggers a
response, which protects drug-responsive melanoma cells
and thereby mediates resilience. In the tumor niche, this
resilience can be further promoted by neighboring ﬁbro-
blasts. We could show that FGF1 activates ﬁbroblasts by
triggering HGF secretion, which has previously been
described as an important resistance-mediating factor in
melanoma28,29. Although the majority of tested cell lines
display FGF1 induction in response to BRAF or MEK
inhibition, this was not observed in M14 cells. Still, the
fact that vemurafenib-conditioned supernatant from M14
cells also stimulates melanoma cells and ﬁbroblasts
implies that other factors might play a protective role in
this cell line. Indeed, preliminary analyses of other growth
factor genes revealed that the ERBB4 ligand NRG3 is
induced by BRAF and MEK inhibitors in M14 cells
(Supplementary Figure 7). The resulting effects will be the
subject of future studies. However, this observation
demonstrates that the upregulation of growth factors
plays an even larger role than anticipated and might affect
BRAF inhibitor resilience even when FGF1 is not
regulated.
Various RTK such as IGF1R39, EGFR10,40, PDGFRα/
β41,42, ERBB37 or MET29 have been related to drug
resistance in melanoma. These activated RTKs are an
alternative means of MEK/ERK1/2 activation, thereby
compensating for the loss of BRAFV600E signaling in
presence of BRAF/MEK inhibitors. In absence of other
oncogenes, RTKs such as EGFR are able to convey potent
pro-tumorigenic features to cells of melanocytic origin43–
46. In contrast, BRAFV600E/K positive melanoma cells tend
to express undetectable or low levels of most RTKs, most
likely because the strong endogenous MAPK activation by
mutant BRAF selects against active RTK signaling to
avoid senescence10. This is changed under drug pressure,
where the expression of various RTKs is beneﬁcial for
survival.
The situation is different for FGFR1, which is expressed
in the majority of melanomas, in contrast to FGFR2-
447(www.proteinatlas.org), thus suggesting that
BRAFV600E/K and FGFR1 expression do not exclude each
other. The existence of FGFR1 expression prior to BRAF
inhibition allows the melanoma cells to react immediately
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on the drug-induced ligands without the need for selec-
tion. This might pave the way for a persistant tumor cell
population (“minimal residual disease”) which then may
develop secondary mechanisms of resistance under con-
tinued BRAF inhibition. The therapeutical targeting of
this core population is therefore an important aim for
reaching a better overall response, which would be the
complete elimination of all tumor cells in a best-case
scenario, and avoiding the advent of resistance. Our data
show that the PI3K pathway is involved in mediating the
expression of FGF1, CCL2, and MMP2. A therapeutic
combination of PI3K or FGFR inhibitors with BRAF/MEK
inhibitors might therefore show enhanced anti-tumor
effects. Combination therapies of BRAF/MEK inhibitors
with PI3K-, CDK4/6-, MET-, and FGFR inhibitors are
currently tested in clinical trials such as within the setting
of the LOGIC-2 trial (https://clinicaltrials.gov/ct2/show/
NCT02159066). However, the LOGIC-2 study design
does not allow the up-front application of any of the
additional inhibitors in a combinatorial approach, but
only as add-on after progression from BRAF/MEK
inhbitor therapy. At this time, the tumor cells are likely to
have already undergone severe drug-triggered selection,
which might impede the therapy success. A ﬁnal evalua-
tion will be possible after completion of the study.
PI3K inhibitors were repeatedly shown to work efﬁ-
ciently in pre-clinical models of melanoma, particularly in
combination with BRAF and/or MEK inhibitors48–50.
Unfortunately, most PI3K inhibitors are not well tolerated
in tumor patients. Interestingly, FGFR inhibition was
previously tested in a mouse melanoma model. The
authors demonstrated that expression of dominant
negative FGFR1 blocks melanoma growth in SCID mice
and that this can be further enhanced by the multi-kinase
inhibitor sorafenib51. In conclusion, we propose that the
parallel inhibition of FGFR with BRAF/MEK inhibitors
might be beneﬁcial for melanoma patients due to the
prevention of drug-induced and secretome-mediated
resilience.
Materials and methods
Cell culture
Melanoma cells A375 and SK-MEL-28 were received
from ATCC, while M14, UACC-62, M19-Mel, SK-MEL-2,
and UACC-257 cells were obtained from the NCI/NIH
(DCTD Tumor Repository, National Cancer Institute at
Frederick, Frederick, MD). Cell line identity was con-
ﬁrmed by genotyping using PowerPlex 16 system (Pro-
mega, Mannheim, Germany). MainUro ﬁbroblasts and
WI-38 cells were received from the Department of Der-
matology, Venereology and Allergology and the Depart-
ment of Biochemistry and Molecular Biology, University
of Würzburg, respectively. Normal human dermal ﬁbro-
blasts (NHDF) were obtained from Promocell (Promocell,
Heidelberg, Germany). Cells were cultivated in Dulbecco’s
modiﬁed Eagle medium (DMEM) supplemented with 10%
FCS and 1x penicillin/streptomycin (Sigma-Aldrich,
Munich, Germany) at 37 °C and 5% CO2 for propagation.
In all experiments containing inhibitors, medium and
inhibitors were replaced after 48 h. BRAF inhibitor
(vemurafenib, Axon Medchem, Groningen, Netherlands),
MEK inhibitors (PD184352 or trametinib, both from
Axon Medchem, Groningen, Netherlands), FGFR inhi-
bitor (AZD 4547, Selleckchem, Munich, Germany), BEZ-
235 (Axon Medchem, Groningen, Netherlands) and
GDC-0941 (Selleckchem, Munich, Germany) were
applied as indicated in the ﬁgure legends.
To determine the inﬂuence of FGF1 on cell lines,
recombinant human protein was used. Cells were starved
in 2% starving medium (DMEM with 2% dialysed FCS,
Gibco/Thermo Fisher Scientiﬁc, Darmstadt, Germany)
and treated for indicated timespans with 100 ng/ml
recombinant FGF1 (Tebu-Bio, Offenbach, Germany).
Generation of vemurafenib-conditioned supernatant
Conditioned supernatant was generated from indicated
melanoma “donor” cells treated with 0.5 µM vemurafenib
or with an equivalent amount of the solvent DMSO in the
controls. After 3 days of treatment, cells were washed
three times with PBS to remove residual vemurafenib
from the medium, and cells were incubated over night
with fresh “starving medium”, containing 2% dialysed FCS
(Gibco/Thermo Fisher Scientiﬁc, Darmstadt, Germany) to
generate conditioned medium. Notably, control cells and
vemurafenib-treated cells were seeded at different cell
densities, which were optimized for each cell line to reach
a similar conﬂuence after the three-day incubation period.
The next day, the medium was ﬁltered through 0.45 µm
membrane ﬁlters and was subsequently applied to
acceptor cells starved for three days in medium contain-
ing 2% dialysed FCS. In previous analyses, we found that a
three-day starving period is optimal to sufﬁciently deprive
cell lines of growth factors present in the serum in order
to enable the responsiveness to auto- or paracrine growth
factors44.
ELISA
To measure the secreted factors, cell supernatant was
concentrated approximately 20-fold with 10 kDa size
exclusion centrifuge colums (Amicon Ultra-4, PLGC
Ultracel-PL; Merck Millipore, Darmstadt, Germany).
CCL2, IL-8, FGF7, FGF1, and HGF were measured with
speciﬁc kits (R&D Systems, Woesbaden, Germany)
according to the manufacturer’s recommendations. Cells
with control medium (i.e., in absence of vemurafenib
(melanoma cells) or FGF1 (MainUro cells)) were used as
controls. Analysis was carried out using the Tecan
microplate reader system.
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Cell lysis and western blot
Cells were lysed in lysis buffer (20mM HEPES (pH 7.8);
500mM NaCl, 5 mM MgCl2, 5 mM KCl; 0.1% deox-
ycholate, 0.5% Nonidet-P40; 10 µg/ml aprotinin; 10 µg/ml
leupeptin; 200 µM Na3VO4; 1 mM
phenylmethanesulphonyl-ﬂuoride and 100mM NaF).
30–50 µg of protein was separated by SDS-PAGE and
analyzed by western blotting. Antibodies directed against
β-actin, P-ERK p42/p44 (Thr202/Tyr204), P-AKT
(Ser473), and MMP2 were received from Cell Signaling
(Danvers, MA, USA) (Supplementary Table 1). The
antibody targeting tubulin was obtained from Sigma
(Taufkirchen, Germany).
MTT assay
Cells were seeded in triplicates in 96-well plates and
were allowed to attach overnight. The next day, treatment
(conditioned medium or FGF1, as indicated in the
respective ﬁgure legend) was started and cells were
incubated for the indicated timespan, before 15 µl of a
5 mg/ml MTT solution (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) was added to each well and
incubated for 2 h. Cells were then lysed with DMSO. The
analysis of the resulting formazan accumulation was done
according to the manufacturer’s recommendations
(Sigma, Taufkirchen, Germany).
Senescence-associated β-galactosidase assay
Cells were incubated under indicated conditions on 6
well-plates and were washed two times with PBS before
staining. For ﬁxation, cells were treated with 3.7% for-
maldehyde in PBS and were subsequently washed twice
with PBS. One microliter of the staining solution (1 mg/
ml X-Gal, 40 mM citric acid/sodium phosphate buffer
(pH 6.0), 5 mM potassium ferricyanide, 5 mM potassium
ferrocyanide, 150mM NaCl, and 2mMMgCl2) was added
per 6-well and the plate was incubated at 37 °C with 5%
CO2 for 16 h protected from light. After subsequent PBS
washing steps, plates were kept at 4 °C until documenta-
tion by light microscopy.
RNA extraction, cDNA synthesis, and real-time PCR
RNA isolation was performed using the RNEasy Kit
(Qiagen, Hilden, Germany) according to the manu-
facturer’s protocol. RNA was reversely transcribed with a
RevertAid First Strand cDNA Synthesis Kit (Thermo
Fisher Scientiﬁc, Waltham, MA, USA). Fluorescence-
based RT-qPCR was performed and analyzed with a
Mastercycler ep Realplex (Eppendorf, Hamburg, Ger-
many) using SYBR Green reagent (Life Technologies,
Darmstadt, Germany). Gene expression was normalized
to ACTB and calculated with the 2ΔΔcT method. Oli-
gonucleotide sequences are indicated in Supplementary
Table 2.
siRNA transfection
Cells were treated with commercially available siRNA
against human FOSL1, (siGENOME SMARTpool,
Thermo Scientiﬁc (Dreieich, Germany) as well as control
siRNA (ON-Target plus Non-Targeting pool, Thermo
Scientiﬁc). X-treme gene transfection reagent (Roche,
Mannheim, Germany) was applied for transfection
according to the manufacturer’s recommendation. The
following day, cells were reseeded for further experiments.
Statistical analysis
Unless indicated otherwise, the graphs depict the mean
values of at least three independent experiments, and
standard deviations are indicated by error bars. One way
ANOVA and Student’s t-test (two-tailed, unpaired)
revealed statistical signiﬁcance highlighted by asterisks
(*p < 0.05; **p < 0.01, ***p < 0.001).
Acknowledgements
The study was supported by the Interdisciplinary Center for Clinical Research of
the University Hospital Würzburg (IZKF B-193) and the Hiege Foundation
against Skin Cancer. This publication was funded by the German Research
Foundation (DFG) and the University of Wuerzburg in the funding programme
"Open Access Publishing".
Author details
1Department of Physiological Chemistry, Biocenter, Würzburg, Germany.
2Department of Dermatology, Venereology and Allergology, University
Hospital Würzburg, Würzburg, Germany. 3Department of Dermatology,
University Hospital Regensburg, Regensburg, Germany. 4Comprehensive
Cancer Center Mainfranken, University Hospital Würzburg, Würzburg, Germany
Conﬂict of interest
The authors declare that they have no conﬂict of interest.
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional afﬁliations.
Supplementary Information accompanies this paper at (https://doi.org/
10.1038/s41389-018-0082-2).
Received: 24 April 2018 Revised: 13 July 2018 Accepted: 6 August 2018
References
1. Corcoran, R. B. et al. BRAF gene ampliﬁcation can promote acquired resistance
to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Sci.
Signal. 3, ra84 (2010).
2. Long, G. V. et al. Increased MAPK reactivation in early resistance to dabrafenib/
trametinib combination therapy of BRAF-mutant metastatic melanoma. Nat.
Commun. 5, 5694 (2014).
3. Shi, H. et al. Acquired resistance and clonal evolution in melanoma during
BRAF inhibitor therapy. Cancer Discov. 4, 80–93 (2014).
4. Wagle, N. et al. MAP kinase pathway alterations in BRAF-mutant melanoma
patients with acquired resistance to combined RAF/MEK inhibition. Cancer
Discov. 4, 61–68 (2014).
5. Haydn, J. M. et al. The MAPK pathway as an apoptosis enhancer in melanoma.
Oncotarget 5, 5040–5053 (2014).
6. Lito, P. et al. Relief of profound feedback inhibition of mitogenic signaling by
RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell
22, 668–682 (2012).
Grimm et al. Oncogenesis  (2018) 7:71 Page 11 of 12
Oncogenesis
7. Abel, E. V. et al. Melanoma adapts to RAF/MEK inhibitors through FOXD3-
mediated upregulation of ERBB3. J. Clin. Invest. 123, 2155–2168 (2013).
8. Boregowda, R. K. et al. The transcription factor RUNX2 regulates receptor
tyrosine kinase expression in melanoma. Oncotarget 7, 29689–29707 (2016).
9. Song, C. et al. Recurrent tumor cell-intrinsic and -extrinsic alterations during
MAPKi-induced melanoma regression and early adaptation. Cancer Discov. 7,
1248–1265 (2017).
10. Sun, C. et al. Reversible and adaptive resistance to BRAF(V600E) inhibition in
melanoma. Nature 508, 118–122 (2014).
11. Falletta, P. et al. Translation reprogramming is an evolutionarily conserved
driver of phenotypic plasticity and therapeutic resistance in melanoma. Genes
Dev. 31, 18–33 (2017).
12. Konieczkowski, D. J. et al. A melanoma cell state distinction inﬂuences sensi-
tivity to MAPK pathway inhibitors. Cancer Discov. 4, 816–827 (2014).
13. Muller, J. et al. Low MITF/AXL ratio predicts early resistance to multiple tar-
geted drugs in melanoma. Nat. Commun. 5, 5712 (2014).
14. Wagle, N. et al. Dissecting therapeutic resistance to RAF inhibition in mela-
noma by tumor genomic proﬁling. J. Clin. Oncol. 29, 3085–3096 (2011).
15. Meierjohann, S. Crosstalk signaling in targeted melanoma therapy. Cancer
Metastas-. Rev. 36, 23–33 (2017).
16. Haferkamp, S. et al. Vemurafenib induces senescence features in melanoma
cells. J. Invest. Dermatol. 133, 1601–1609 (2013).
17. Li, Z. et al. Encorafenib (LGX818), a potent BRAF inhibitor, induces senescence
accompanied by autophagy in BRAFV600E melanoma cells. Cancer Lett. 370,
332–344 (2016).
18. Coppe, J. P., Desprez, P. Y., Krtolica, A. & Campisi, J. The senescence-associated
secretory phenotype: the dark side of tumor suppression. Annu. Rev. Pathol. 5,
99–118 (2010).
19. Kuilman, T. et al. Oncogene-induced senescence relayed by an interleukin-
dependent inﬂammatory network. Cell 133, 1019–1031 (2008).
20. Ohanna, M. et al. Senescent cells develop a PARP-1 and nuclear factor-{kappa}
B-associated secretome (PNAS). Genes Dev. 25, 1245–1261 (2011).
21. Davalos, A. R., Coppe, J. P., Campisi, J. & Desprez, P. Y. Senescent cells as a
source of inﬂammatory factors for tumor progression. Cancer Metastas-. Rev.
29, 273–283 (2010).
22. Ohanna, M. et al. Secretome from senescent melanoma engages the STAT3
pathway to favor reprogramming of naive melanoma towards a tumor-
initiating cell phenotype. Oncotarget 4, 2212–2224 (2013).
23. Long, G. V. et al. Dabrafenib plus trametinib versus dabrafenib monotherapy in
patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival
and safety analysis of a phase 3 study. Ann. Oncol. 28, 1631–1639 (2017).
24. Ferguson, J., Arozarena, I., Ehrhardt, M. & Wellbrock, C. Combination of MEK
and SRC inhibition suppresses melanoma cell growth and invasion. Oncogene
32, 86–96 (2013).
25. Sher, I. et al. Identiﬁcation of residues important both for primary receptor
binding and speciﬁcity in ﬁbroblast growth factor-7. J. Biol. Chem. 275,
34881–34886 (2000).
26. Zhang, X. et al. Receptor speciﬁcity of the ﬁbroblast growth factor family. The
complete mammalian FGF family. J. Biol. Chem. 281, 15694–15700 (2006).
27. Joseph, E. W. et al. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor
cell proliferation in a V600E BRAF-selective manner. Proc. Natl Acad. Sci. USA
107, 14903–14908 (2010).
28. Rohrbeck, L. et al. Hepatocyte growth factor renders BRAF mutant human
melanoma cell lines resistant to PLX4032 by downregulating the pro-
apoptotic BH3-only proteins PUMA and BIM. Cell Death Differ. 23, 2054–2062
(2016).
29. Straussman, R. et al. Tumour micro-environment elicits innate resistance to
RAF inhibitors through HGF secretion. Nature 487, 500–504 (2012).
30. Wilson, T. R. et al. Widespread potential for growth-factor-driven resistance to
anticancer kinase inhibitors. Nature 487, 505–509 (2012).
31. Gopal, Y. N. et al. Basal and treatment-induced activation of AKT mediates
resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human
cutaneous melanoma cells. Cancer Res. 70, 8736–8747 (2010).
32. Paraiso, K. H. et al. PTEN loss confers BRAF inhibitor resistance to melanoma
cells through the suppression of BIM expression. Cancer Res. 71, 2750–2760
(2011).
33. Obenauf, A. C. et al. Therapy-induced tumour secretomes promote resistance
and tumour progression. Nature 520, 368–372 (2015).
34. Maurus, K. et al. The AP-1 transcription factor FOSL1 causes melanocyte
reprogramming and transformation. Oncogene 36, 5110–5121 (2017).
35. Yang, H. et al. RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays
potent antitumor activity in preclinical melanoma models. Cancer Res. 70,
5518–5527 (2010).
36. Sun, X. et al. Senescence-associated secretory factors induced by cisplatin in
melanoma cells promote non-senescent melanoma cell growth through
activation of the ERK1/2-RSK1 pathway. Cell Death Dis. 9, 260 (2018).
37. Beck, D. et al. Vemurafenib potently induces endoplasmic reticulum stress-
mediated apoptosis in BRAFV600E melanoma cells. Sci. Signal. 6, ra7 (2013).
38. Eigner, K. et al. The unfolded protein response impacts melanoma progression
by enhancing FGF expression and can be antagonized by a chemical cha-
perone. Sci. Rep. 7, 17498 (2017).
39. Villanueva, J. et al. Acquired resistance to BRAF inhibitors mediated by a RAF
kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/
PI3K. Cancer Cell 18, 683–695 (2010).
40. Girotti, M. R. et al. Inhibiting EGF receptor or SRC family kinase signaling
overcomes BRAF inhibitor resistance in melanoma. Cancer Discov. 3, 158–167
(2013).
41. Nazarian, R. et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by
RTK or N-RAS upregulation. Nature 468, 973–977 (2010).
42. Sabbatino, F. et al. PDGFRalpha up-regulation mediated by sonic hedgehog
pathway activation leads to BRAF inhibitor resistance in melanoma cells with
BRAF mutation. Oncotarget 5, 1926–1941 (2014).
43. Leikam, C. et al. Cystathionase mediates senescence evasion in melanocytes
and melanoma cells. Oncogene 33, 771–782 (2014).
44. Laisney, J. A., Mueller, T. D., Schartl, M. & Meierjohann, S. Hyperactivation of
constitutively dimerized oncogenic EGF receptors by autocrine loops. Onco-
gene 32, 2403–2411 (2013).
45. Meierjohann, S., Mueller, T., Schartl, M. & Buehner, M. A structural model of the
extracellular domain of the oncogenic EGFR variant Xmrk. Zebraﬁsh 3,
359–369 (2006).
46. Schaafhausen, M. K. et al. Tumor angiogenesis is caused by single melanoma
cells in a manner dependent on reactive oxygen species and NF-kappaB. J.
Cell Sci. 126, 3862–3872 (2013).
47. Giehl, K. A., Nagele, U., Volkenandt, M. & Berking, C. Protein expression of
melanocyte growth factors (bFGF, SCF) and their receptors (FGFR-1, c-kit) in
nevi and melanoma. J. Cutan. Pathol. 34, 7–14 (2007).
48. Deuker, M. M. & McMahon, M. Rational targeting of BRAF and PI3-Kinase
signaling for melanoma therapy. Mol. Cell. Oncol. 3, e1033095 (2016).
49. Krepler, C. et al. A comprehensive patient-derived xenograft collection
representing the heterogeneity of melanoma. Cell Rep. 21, 1953–1967 (2017).
50. Niessner, H. et al. PI3K pathway inhibition achieves potent antitumor activity in
melanoma brain metastases in vitro and in vivo. Clin. Cancer Res. 22,
5818–5828 (2016).
51. Metzner, T. et al. Fibroblast growth factor receptors as therapeutic targets in
human melanoma: synergism with BRAF inhibition. J. Invest. Dermatol. 131,
2087–2095 (2011).
Grimm et al. Oncogenesis  (2018) 7:71 Page 12 of 12
Oncogenesis
